Achillion Announces Proposed Secondary Offering of Common Stock
November 14 2017 - 4:03PM
Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ:ACHN) today
announced that Johnson & Johnson Innovation-JJDC, Inc.
(“JJDC”), an existing stockholder of Achillion, intends to offer
for sale in an underwritten public offering 18,367,346 shares of
Common Stock of Achillion, which constitutes all of JJDC’s equity
position in Achillion. Achillion will not sell any shares or
receive any proceeds from the offering, and the total number of
shares of its outstanding common stock will not change as a result
of the offering.
Goldman Sachs & Co. LLC and Leerink Partners
LLC are acting as the joint book-running managers for the proposed
offering. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
The public offering will be made pursuant to a
shelf registration statement, including a prospectus, on Form S-3
(File No. 333-216197) that was filed by Achillion with the
Securities and Exchange Commission (the “SEC”) on February 23, 2017
and declared effective on April 28, 2017, and a preliminary
prospectus supplement related to the offering. The preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC’s website at www.sec.gov. When available, copies of the
preliminary prospectus supplement related to the offering and the
accompanying prospectus may be obtained by contacting Goldman Sachs
& Co. LLC, Prospectus Department, 200 West Street, New York,
New York 10282, via telephone: 1-866-471-2526 or email:
prospectusgroup-ny@ny.email.gs.com or Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, telephone: (800) 808-7525, ext. 6132, email:
syndicate@Leerink.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy any securities, nor
shall there be any sale of these securities, in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. Offers
will be made only by means of a prospectus supplement and the
accompanying prospectus forming a part of the registration
statement.
About Achillion Pharmaceuticals,
Inc.Achillion is a science-driven, patient-focused company
seeking to leverage its strengths across the continuum from
discovery to commercialization in its goal of providing better
treatments for people with serious diseases.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995 that are based on current
expectations, forecasts and assumptions that involve risks and
uncertainties. Forward-looking statements include statements
regarding Achillion’s expectations, beliefs, intentions or
strategies regarding the future, and can be identified by
forward-looking words such as “anticipate,” “believe,” “could,”
“continue,” “estimate,” “expect,” “intend,” “may,” ‘should,” “will”
and “would” or similar words. Forward-looking statements in
this press release include, without limitation, statements
regarding the completion of the offering. Important factors could
cause actual results to differ materially from these
forward-looking statements, including market conditions as well as
risks and uncertainties associated with Achillion’s business,
including those risks and uncertainties described in “Risk Factors”
in Achillion's preliminary prospectus supplement and in “Risk
Factors” and elsewhere in Achillion’s annual report on Form 10-K
for the year ended December 31, 2016, and Quarterly Report for the
quarter ended September 30, 2017, each of which has been filed with
the SEC, as well as in other filings that Achillion periodically
makes with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Achillion
anticipates that subsequent events and developments will cause its
views to change. While Achillion may elect to update these
forward-looking statements at some point in the future, Achillion
expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investors & Media:
Glenn Schulman, PharmD, MPH
Executive Director, Investor Relations
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
gschulman@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024